Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 5/20 | 0.55 |
| ▸ | LHCGR | P22888 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725610 | 0.85 | P2RX7 (0.55) | FPR1LHCGRSMN1; SMN2MAPTFPR2 | |
| SCHEMBL779917 | 0.84 | CHRNA7 (0.72) | CHRNA7KCNH2 | |
| SCHEMBL3939398 | 0.84 | CHRNA7 (0.72) | CHRNA7KCNH2 | |
| Hydrochloric Acid SCHEMBL779395 | 0.83 | KCNH2 (0.72) | CHRNA7KCNH2 | |
| Hydrochloric Acid SCHEMBL779636 | 0.83 | KCNH2 (0.72) | CHRNA7KCNH2 | |
| SCHEMBL16177977 | 0.80 | CHRNA7 (0.58) | CHRNA7SMN1; SMN2KCNH2MAPTALDH1A1 | |
| SCHEMBL7464685 | 0.80 | USP19 (0.46) | CHRNA7SMN1; SMN2KCNH2 | |
| SCHEMBL16163650 | 0.80 | CHRNA7 (0.66) | CHRNA7SMN1; SMN2KCNH2MAPT | |
| SCHEMBL14833502 | 0.79 | MMP1 (0.44) | CHRNA7SMN1; SMN2KCNH2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28230857 | 0.78 | RAB9A (0.51) | SMN1; SMN2KCNH2MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-8822472-B2 | Piperazines, pharmaceutical compositions and methods of use thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | FPR1 1142/4885LHCGR 1593/4885CHRNA7 1/4885 |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | FPR1 1044/4885LHCGR 2149/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.